Enhancing Letter-Speech Sound Learning and Reading Network Activation With Transcranial Electrical Stimulation (LexiStim)

May 19, 2026 updated by: Silvia Brem

Transcranial Electrical Stimulation and the Reading Brain: Toward Novel Interventions for Reading Impairments

This study investigates the effects of transcranial electrical stimulation (tES) on the brain and its potential to enhance reading-related learning. Adult participants with a range of reading abilities will receive transcranial random noise stimulation (tRNS) while they perform an artificial orthography learning task. This task simulates letter-speech sound learning, an important first step during reading acquisition known to be impaired in individuals with developmental dyslexia. The effects of the intervention will be assessed using both behavioral measures and functional magnetic resonance imaging (fMRI).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study investigates the effects of transcranial electrical stimulation (tES) on the brain and its potential to enhance reading-related learning. The aim is to identify novel techniques for treating developmental dyslexia, which is a common learning disorder that occurs in childhood and can persist into adulthood. Typically, standard therapy for dyslexia consists of specific reading exercises; however, such training often does not fully remediate the difficulties.

This study, therefore, evaluates how transcranial electrical stimulation may be applied to support learning and ultimately reading. During the stimulation, participants perform an artificial orthography learning task simulating letter-speech sound learning. Whereas previous tES reading studies have focused primarily on behavioral outcomes, the present study additionally measures brain activity using fMRI to elucidate how tES affects neural processing and how these effects may relate to reading abilities.

The knowledge gained from this project is intended to support the future development of transcranial electrical stimulation as an intervention for adults and children with developmental dyslexia.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
60

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Switzerland
      • Zurich, Switzerland
        • Recruiting
        • University Hospital of Psychiatry

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age 18-35
  • All genders
  • Written informed consent by the participant
  • German speaking (native)
  • Right-handed

Exclusion Criteria:

  • Diagnoses of neurological disorders, intellectual disabilities, or psychiatric disorders (We do not exclude participants with common comorbidities of dyslexia, specifically dyscalculia, Attention Deficit/Hyperactivity Disorder, or Autism Spectrum Disorders)
  • History of any acquired brain damage or evidence of fetal alcohol syndrome
  • Hearing problems and vision problems that cannot be corrected
  • Inability to follow procedures or understand the instructions given in (Swiss-)German
  • Current use of psychoactive medications or substances, or a history of substance abuse that may affect brain function, performance or MRI signal quality
  • A nonverbal IQ < 80
  • Having previously participated in a transcranial electrical stimulation study
  • Knowledge to read or write in a language using foreign letters (i.e., different from the Latin alphabet)
  • Contraindications to brain stimulation or MRI, such as: History of epilepsy or severe migraine; Skull breach such as craniotomy; Wearing neurostimulators or cardiac pacemakers; Wearing hearing aid devices or cochlear implants, which are not MR safe; Having metal pieces in their body (e.g., piercings that cannot be removed and contain metal, screws or plates from surgical operations, wounds from metal splinters or similar); Claustrophobia or problems lying in the scanner (e.g., pain, anxiety); Previous surgery on the head or heart; Being pregnant (a pregnancy test will be conducted at the MR center before the measurement if a female participant suspects she might be pregnant or is uncertain about her pregnancy status according to the Swiss Ethics Leitlinie:

https://swissethics.ch/assets/pos_papiere_leitfaden/20110906_kek_mri.pdf); Having problems lying still (strong cold, tremor, etc.); Wearing non-removable dental braces

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Real Stimulation
Participants will receive transcranial random noise stimulation (tRNS) applied to the left superior temporal gyrus.
Other: Transcranial random noise stimulation
Participants will receive high-frequency tRNS (max. 1.5 mA) applied to the left superior temporal gyrus. A high-definition setup (3x1 electrodes) will be used to achieve more focal stimulation. Stimulation will be applied during an artificial orthography learning task with simultaneous fMRI acquisition.
Sham Comparator: Sham Stimulation
Participants in this group will serve as the control condition. The setup will be identical to the active stimulation group, but stimulation will be sham, such that no electrical current will be applied for the duration of the session.
Other: Sham Stimulation
Participants will also have electrodes placed on their scalp. The setup is programmed to induce a short ramp-up of the chosen electrical current followed by a ramp-down at the beginning and at the end of the stimulation. In between, no current will be applied. Sham stimulation will be applied during an artificial orthography learning task with simultaneous fMRI acquisition.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Performance in the artificial orthography learning task
Time Frame: At second session, up to 8 weeks after baseline
Performance on the artificial orthography learning task and the artificial orthography reading fluency test will be compared between the stimulation and sham groups.
At second session, up to 8 weeks after baseline
fMRI activation and connectivity during print processing
Time Frame: At baseline (Session 1) and at second session, up to 8 weeks after baseline
fMRI activation and connectivity of the posterior superior temporal gyrus and other regions of the reading and audiovisual learning networks will be compared before, during and after transcranial electrical stimulation (tES). The fMRI tasks performed in the second session include artificial orthography learning and explicit print processing (lexical decision task), whereas implicit print processing (one-back task) is performed both at baseline and in the second session. These changes in activation and connectivity will be compared between the stimulation group and the sham group.
At baseline (Session 1) and at second session, up to 8 weeks after baseline

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
fMRI brain activation and connectivity in further fMRI tasks: audiovisual processing and naturalistic movie watching
Time Frame: At baseline (Session 1) and at second session, up to 8 weeks after baseline
Brain activation and connectivity during further fMRI tasks, namely an audiovisual localizer task and a movie-watching paradigm, will be investigated and compared between the two groups. The audiovisual localizer task focuses on brain activation in reading and audiovisual processing regions, and the movie-watching paradigm on connectivity within the resting-state networks.
At baseline (Session 1) and at second session, up to 8 weeks after baseline
Reading and reading-related behavioral measures
Time Frame: At baseline (Session 1) and at second session, up to 8 weeks after baseline
Reading and reading-related tasks, such as word and pseudoword reading, will be performed before and after tES to provide a behavioral estimate of reading skills.
At baseline (Session 1) and at second session, up to 8 weeks after baseline
Performance in further cognitive tasks
Time Frame: At baseline (Session 1) and at second session, up to 8 weeks after baseline
The performance in further cognitive tasks (working memory, attention, rapid automatized naming) will be compared before and after tES.
At baseline (Session 1) and at second session, up to 8 weeks after baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Silvia Brem

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Swiss National Science Foundation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 23, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2027

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 9, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 22, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 22, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 19, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • BASEC2025-01540

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dyslexia

Clinical Trials on Transcranial random noise stimulation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings